Sap Se Stock News

SAP said on Thursday it has agreed to buy a majority stake in privately held U.S. fintech firm Taulia as the German business software group seeks to expand its presence across supply-chain financing a

SAP (SAP) and Icertis announced an expanded partnership for enhanced contract management to help companies increase efficiency, minimize risk and realize the full intent of their agreements.

SAP's stock declined by 1.2% to $136 in the last twenty-one trading days. In comparison, as per Trefis SAP's Valuation is $151.

Stocks Analysis by Zacks Investment Research covering: Microsoft Corporation, SAP SE, Salesforce.com Inc, Hewlett Packard Enterprise Co. Read Zacks Investment Research''s latest article on Investing.com

SAP will utilize the new share buyback plan to fund awards under the "Move SAP" share-based compensation scheme from 2022.

SAP's Q4 performance benefits from strength in its cloud business, especially the strong adoption of the company's "Rise with SAP" solution.

SAP (SAP) has announced a €1B share repurchase program, to be executed in the period between February 01 and December 31, 2022.The program follows SAP''s 2020 repurchase of around 14M…

SAP (SAP) has climbed +2.27% in after-hours trading after reporting preliminary results for Q4 and FY21.The software firm delivered record cloud performance, with cloud revenue up 28%…

German business software group SAP on Thursday reported a 28% revenue increase in its cloud business in the fourth quarter, as the growth of its cloud business database accelerated with more customers

SAP SE shares ticked higher in the extended session Thursday after the business software company released preliminary results of its fourth-quarter results.

Though SAP works to secure the supply chain and provides basic zero trust for its infrastructure, they fall short of what enterprises need.

TORONTO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (NASDAQ: FTRP , TSX: FTRP ) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced that it will begin making applications for Canadians in need to access psilocybin-assisted and MDMA-assisted therapy through Health Canada''s Special Access Program (SAP). The announcement follows amendments to the SAP announced in the Canada Gazette on January 5, 2022, which have enabled physicians in Canada to make applications to Health Canada for access to "restricted drugs", including psilocybin and MDMA. The SAP provides physicians treating patients with "serious or life-threatening conditions" with the ability to request access to drugs that have not yet been approved for sale in Canada when conventional therapies have failed, are unsuitable, or unavailable. Prior to the amendments, restricted drugs such as psilocybin and MDMA were not accessible through SAP. Field Trip, which presently operates three Field Trip Health Centers in Canada (Toronto, Vancouver and Fredericton), eight in the United States and one in The Netherlands, was actively involved in providing feedback and commentary to Health Canada on the proposed revisions to the SAP during the 60-Day Public Comment Period, and was involved in having Health Canada recognize that treatment resistant depression, as well as mental health and central nervous conditions such as cluster headaches and migraines, will be considered "serious or life-threatening conditions" for purposes of the SAP.

VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL ), (OTC: CLABF ), (Frankfurt: LD6 , WKN: A3CSSU) (the " Company " or " Core One ") applauds Health Canada for its recent amendment to the Special Access Programme ( SAP ), which will now allow physicians to request patient access to psychedelic treatments, including psilocybin-assisted therapy. The amendments under the SAP came into effect as of today, January 5, 2022, as published in the Canada Gazette, and allows physicians to request psychedelic treatments on behalf of their patients, on a case-by-case basis, for serious treatment-resistant or life-threatening conditions. This significant amendment has the potential to provide numerous Canadians struggling with serious mental health afflictions with alternative therapies where traditional treatments have failed, or where other treatments are unsuitable or are unavailable in Canada. Canada''s SAP was designed with the purpose of allowing people access to new, potentially life-saving medications before they are formally approved for routine use in healthcare, however prior to today''s milestone amendment, psychedelic medications have been ineligible for Special Access Programme applications.

SAP amendment allows practitioners to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis SAP amendment allows practitioners to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis

VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI ) (OTCQB: OPTHF ) (FRA: 8BN) ("Optimi" or the "Company"), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report the successful completion of the Health Canada inspection on December 21, 2021. The Company is in close contact with the regulator and welcomes finalization of the process in the coming weeks. Additionally, Optimi commends Health Canada for taking an active leadership role in finding solutions for the ongoing Canadian mental health crisis including access to psilocybin for therapeutic purposes through the Special Access Program (SAP). Background In Canada, drugs are authorized for sale only once they have successfully gone through the drug review process, including evaluation of safety, effectiveness and quality. However, Health Canada''s SAP allows practitioners to request access to drugs that are not available in Canada for the emergency treatment of patients with serious or life-threatening conditions who have exhausted other treatment options.